Outlook Therapeutics (OTLK) Stock Statistics & Valuation Metrics

Outlook Therapeutics has a market cap or net worth of $40.25M. The enterprise value is -$7.53T.

Outlook Therapeutics has 120,863,250 shares outstanding. The number of shares has decreased by -2.65% in one year.

Outlook Therapeutics’s return on equity (ROE) is 1.94 and return on invested capital (ROIC) is -2357.61%.

The current PE Ratio of Outlook Therapeutics is ―. Outlook Therapeutics’s PEG ratio is 0.01.

In the last 12 months, Outlook Therapeutics had revenue of 1.41M and earned -62.42M in profits. Earnings per share was -1.79.

In the last 12 months, operating cash flow was -22.77T and capital expenditures 0.00, giving a free cash flow of -22.77T billion.

Outlook Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Outlook Therapeutics upcoming earnings date is Aug 13, 2026, TBA (Confirmed).

Outlook Therapeutics as a current ratio of 0.38, with Debt / Equity ratio of -0.76%

In the past 12 months, Outlook Therapeutics has paid -1.55M in taxes.

Outlook Therapeutics EV to EBITDA ratio is -0.93, with an EV/FCF ratio of >-0.01.

Outlook Therapeutics has $7.75T in cash and marketable securities with $218.96B in debt, giving a net cash position of $7.53T billion.

Gross margin is -17.18%, with operating margin of -4744.25%, and net profit margin of -4416.22%.

The average price target for Outlook Therapeutics is $3.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy